Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 197-206

  Mantovani, Giovanni ^a   Massa, Elena ^a   Astara, Giorgio ^a   Murgia, Viviana ^a   Gramignano, Giulia ^a   Lusso, Maria Rita ^a   Camboni, Paolo ^a   Ferreli, Luca ^a   Mocci, Miria ^a   Perboni, Simona ^a   Mura, Loredana ^a   Madeddu, Clelia ^a   Macciò, Antonio ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Sirai Hospital   (Italy)

Author keywords

Chemotherapy and chemoradiotherapy; Head and neck cancer; Oral mucositis; Topical GM CSF

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LEPTIN;

ADULT; AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; ECONOMICS; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; MOUTH MUCOSA; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RADIATION INJURY; STOMATITIS; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2; LEPTIN; MALE; MIDDLE AGED; MOUTH MUCOSA; RADIATION INJURIES; STOMATITIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037918027     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.197     Document Type: Article

References (34)

1. Kostler WJ, Hejna M, Wenzel C and Zielinski CC: Oral mucositis complicating chemotherapy and/or radiotherapy. CA Cancer J Clin 51: 290-315, 2001.
2. Peterson DE: Research advances in oral mucositis. CUIT Opin Oncol 11: 261-266, 1999. (Pubitemid 29312745)
3. Trotti A: Toxicity in organ preservation in head and neck cancer. 35th Annual Meeting Educational Book. Am Soc Clin Oncol: 557-562, 1999.
4. Cox JD, Pajak TF, Marcial VA, et al: Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer 69: 2744-2748, 1992.
5. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90: 1205-1211, 1998. (Pubitemid 28407086)
6. Woo SB, Sonis ST and Sonis AL: The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. Cancer 66: 2375-2379, 1990.
7. Jansma J, Vissink A, Spijkervet FK, et al: Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 70: 2171-2180, 1992.
8. Bez C, Demarosi F, Sardella A, et al: GM-CSF mouthrinses in the treatment of severe oral mucositis: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88: 311-315, 1999.
9. Lira-Puerto V, Silva A, Martinez A, et al: Grade 3-4 stomatitis succesfully treated with local GM-CSF (Leukomax). Ann Oncol 5: 207-208, 1994.
10. Nicolatou-Galitis O, Dardoufas K, Markoulatos P, et al: Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. J Oral Pathol Med 30: 471-480, 2001. (Pubitemid 32752287)
11. Vokes EE, Kies M, Haraf DJ, et al: Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of disease. J Clin Oncol 13: 876-883, 1995.
12. Mantovani G, Proto E, Massa E, et al: Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study with organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol 20: 419-427, 2002.
13. Caponigro F, Massa E, Manzione L, et al: Docetaxel and cisplatin in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 12: 199-202, 2001. (Pubitemid 32223868)
14. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al: Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 17: 1008-1019, 1999. (Pubitemid 29109335)
15. Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Santona MC and del Giacco GS: Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 25: 135-141, 1995.
16. Mantovani G, Macciò A, Esu S, et al: Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33: 602-607, 1997. (Pubitemid 27223745)
17. Mantovani G, Macciò A, Lai P, Massa E, Ghiani M and Santona MC: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxy-progesterone acetate. Semin Oncol 25 (Suppl. 6): 45-52, 1998. (Pubitemid 28268504)
18. Mantovani G, Macciò A, Madeddu C, et al: Serum values of proinflammatory cytokines inversely correlate with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 79: 406-414, 2001. (Pubitemid 32692637)
19. Vokes EE, Haraf DJ and Kies MS: The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol 27: 34-38, 2000. (Pubitemid 30643363)
20. Sonis ST: Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34: 39-43, 1998.
21. Berger AM and Kilroy TJ: Adverse effects of treatment. Section 2: oral complications. In: Cancer: Principles and Practice of Oncology. De Vita VT Jr, Hellman S and Rosenberg SA (eds). 5th edition. Lippincott-Raven, Philadelphia, New York, pp2714-2725, 1997.
22. Neema JP, Baboo HA and Shah PM: Radiation mucositis: prevention and treatment with special reference to the use of GM-CSF. J Assoc Physicians India (Suppl. 3): 14, 1995.
23. Hejna M, Brodowicz T and Zielinski CC: Local use of GM-CSF for severe mucositis. Eur J Cancer 35: S14-S17, 1999.
24. Chi KH, Chen CH, Chan WK, et al: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 13: 2620-2628, 1995.
25. Rosso M, Blasi G, Gherlone E and Rosso R: Effect of granulocyte- macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemoradiotherapy. J Chemother 9: 382-385, 1997. (Pubitemid 27469650)
26. Kannan V, Bapsy PP, Anantha N, et al: Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys 37: 1005-1010, 1997. (Pubitemid 27230023)
27. Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R and Coccia P: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 12: 1917-1922, 1994. (Pubitemid 24349395)
28. Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J and Joensuu H: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys 46: 525-534, 2000. (Pubitemid 30100628)
29. Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, Kyprianou K, Kolitsi G and Dardoufas K: A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Int J Radiat Oncol Biol Phys 42: 551-556, 1998. (Pubitemid 28501104)
30. Rovirosa A, Ferre J and Biete A: Granulocyte macrophage-colony- stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys 41: 747-754, 1998. (Pubitemid 28285950)
31. Ibrahim EM and al-Mulhim FA: Effect of granulocyte macrophage-colony- stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Med Oncol 14:47-51,1997. (Pubitemid 27293864)
32. Hejna M, Kostler WJ, Raderer M, et al: Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer 37: 1994-2002, 2001. (Pubitemid 32938101)
33. Cartee L, Petros PP, Rosner GL, et al: Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 7: 471-477, 1995.
34. Sprinzl GM, Galvan O, de Vries A, et al: Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 37: 2003-2009, 2001. (Pubitemid 32938102)